- Home
- SAN vs NVO Comparison
SAN vs NVO Comparison
Compare SAN & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAN | NVO |
|---|---|---|
| Founded | 1857 | 1923 |
| Country | Spain | Denmark |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.7B | 203.2B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | SAN | NVO |
|---|---|---|
| Price | $14.73 | $46.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $51.00 |
| AVG Volume (30 Days) | ★ 18.7M | 12.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | 1.54% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.53 | N/A |
| Revenue Next Year | $6.55 | $3.70 |
| P/E Ratio | ★ $11.21 | $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.45 | $35.12 |
| 52 Week High | $15.00 | $64.16 |
Technical Indicators
Market Signals| Indicator | SAN | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 50.43 |
| Support Level | $11.75 | $43.25 |
| Resistance Level | $15.00 | $48.23 |
| Average True Range (ATR) | 0.21 | 0.97 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 73.05 | 54.40 |
Price Performance
Historical ComparisonAbout SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.